The impact of exogenous estrogen exposure on the characteristics of estrogen receptor (ER) positive, early-stage breast cancer (EBC).

Authors

null

Orly Yariv

Rabin Medical Center, Petah Tikva, Israel

Orly Yariv , Rinat Yerushalmi , Assaf Moore , Tzippy Shohat , Ofer Rotem , Korzets Ceder Yasmin , Hadar Goldvaser

Organizations

Rabin Medical Center, Petah Tikva, Israel, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel, Tel Aviv University, Tel Aviv, Israel, Beilinson Hospital, Statistical Consulting Unit, Petach Tikva, Israel, Thoracic Oncology Service, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel, Beilinson Hosp 32393 Shem, Petach Tikva, Israel, Rabin Medical Center, Beilinson Hospital, Davidoff Center, Kyriat Ono, Israel

Research Funding

No funding received
None

Background: Oral contraceptives (OC) and hormone replacement therapy (HRT) are well-established risk factors for ER positive breast cancer. Infertility is associated with an increased breast cancer risk and there is conflicting data on the influence of fertility treatments on breast cancer risk. The impact of exogenous estrogen exposure on breast cancer characteristics is not well described. Methods: A single center retrospective cohort study comprising all women with ER positive, human epidermal growth factor receptor 2 (HER2) negative, EBC whose tumors were sent to OncotypeDX analysis treated in our institute between 2005 and 2012. Data on exogenous estrogen exposure were collected including: OC and HRT use and prior fertility treatments. The impact of these exposures was assessed on pre-specified histopathological features including: tumor size, nodal status, ER and progesterone receptor (PR) staining, grade, Oncotype recurrence score (RS), ki67, lymphovascular and perineural invasion. Results: A total of 620 women were included, 79% were postmenopausal. Prior exposure to OC, HRT and fertility treatments was documented in 19% (103), 30% (136) and 11% (62), respectively. OC use was associated with smaller (≤1cm) tumors (30% vs. 20%, p = 0.023) and were less likely to have grade 3 disease (10% vs. 19%, p = 0.049). No other associations were found between exogenous estrogen exposures and tumor characteristics (Table). Conclusions: Use of OC may be associated with breast cancer with a distinct features compared to women with luminal breast cancer without history of OC use. Large scale studies are needed to better characterize these findings.

OC
HRT
HRT ≥ 2 years
Fertility treatment
Yes
(%)
No
(%)
PYes
(%)
No
(%)
PYes
(%)
No
(%)
PYes
(%)
No
(%)
P
T≤1 cm
1 < T≤2
T > 2 cm
30
44
26
20
57
23
0.02324
56
20
22
55
23
0.70020
57
24
23
55
22
0.70022
54
25
21
65
15
0.172
Node positive15180.66721150.09820150.09818170.859
IDC
ILC
Other
87
9
5
79
14
8
0.20777
15
9
82
13
5
0.29976
15
9
82
12
6
0.29989
11
0
79
13
8
0.064
Grade
1
2
3
18
73
10
18
63
19
0.04917
62
21
16
67
17
0.50016
64
19
16
67
18
0.50014
73
13
18
64
18
0.167
ER intensity
≤1
1 < ER < = 2
ER > 2
3
22
75
2
22
77
0.7392
21
78
1
17
81
0.7081
22
77
1
17
81
0.7083
29
68
2
20
78
0.189
PR
Negative
8140.10314160.67115160.6717140.112
LVI present5100.056750.351870.351760.772
Ki67
> 20%
18220.52818230.36219220.36229200.186
Oncotype RS > 2516180.57018170.78716180.78718170.859

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Publication Only

Session Title

Publication Only: Breast Cancer - Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Local-Regional Therapy

Citation

J Clin Oncol 38: 2020 (suppl; abstr e12606)

DOI

10.1200/JCO.2020.38.15_suppl.e12606

Abstract #

e12606

Abstract Disclosures